Oramed Pharmaceuticals In...

NASDAQ: ORMP · Real-Time Price · USD
2.06
-0.01 (-0.48%)
At close: Aug 20, 2025, 3:59 PM

Oramed Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Nov 30, 2021 Aug 31, 2021 May 31, 2021 Feb 28, 2021
Revenue
2M 2M n/a n/a n/a 674K 1.34M 2.02M 2.7M 2.7M 2.7M 2.7M 2.7M 2.7M 2.7M 2.7M 2.7M 2.7M
Cost of Revenue
2.05M 2.02M 31K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Gross Profit
-48K -18K -31K n/a n/a 674K 1.34M 2.02M 2.7M 2.7M 2.7M 2.7M 2.7M 2.7M 2.7M 2.7M 2.7M 2.7M
Operating Income
-13.67M -14.32M -12.78M -13.06M -12.87M -13.52M -15.77M -21.63M -26.93M -34.55M -40.6M -38.92M -38.14M -32.84M -26.46M -24.22M -19.83M -15.99M
Interest Income
-3.96M -5.09M n/a 37.71M 38.14M 26.39M 22.89M 4.51M 4.08M 1.95M 894K 1.03M 1.03M 681K 137K n/a 121K 321K
Pretax Income
-22.22M -24.51M -15.92M 7.16M 22.38M 10.23M 5.09M -16.94M -20.81M -30.57M -37.66M -37.03M -37.06M -31.62M -25.52M -22.99M -18.8M -15.46M
Net Income
-24.16M -28.24M -19.06M 4.46M 20.86M 10.46M 7.12M -14.76M -18.79M -28.13M -36.75M -36.1M -35.7M -30.38M -24.56M -22.24M -18.38M -15.46M
Selling & General & Admin
6.74M 6.98M 6.46M 6.43M 7.52M 8.47M 8.14M 9.17M 10.76M 11.03M 15.66M 14.84M 13.57M 11.95M 7.53M 5.94M 4.42M 4.15M
Research & Development
6.94M 7.35M 6.32M 6.63M 5.34M 5.72M 8.97M 14.48M 18.87M 26.23M 27.64M 26.77M 27.27M 23.59M 21.63M 20.99M 18.11M 14.54M
Other Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
13.69M 14.33M 12.78M 13.06M 12.87M 14.2M 17.11M 23.65M 29.63M 37.26M 43.3M 41.61M 40.84M 35.54M 29.16M 26.93M 22.53M 18.69M
Interest Expense
2.56M 2.82M 853K 17.48M 2.89M 2.63M 2.04M 826K 1.04M 1.39M 1.93M 2.1M 1.07M 1.21M 928K 1.01M 1.15M 661K
Selling & Marketing Expenses
n/a n/a n/a n/a -663K -471K -287K 131K 1.26M 1.45M 1.85M 2.02M 1.55M 1.18M 585K n/a n/a n/a
Cost & Expenses
15.67M 16.32M 12.78M 13.06M 12.87M 14.2M 17.11M 23.65M 29.63M 37.26M 43.3M 41.61M 40.84M 35.54M 29.16M 26.93M 22.53M 18.69M
Income Tax Expense
2.01M 3.77M 3.18M 2.77M 2.01M 254K -1.56M -1.75M -2.02M -2.44M -910K -925K -1.36M -1.24M -1.22M -1.27M -1.07M -643K
Shares Outstanding (Basic)
41.74M 41.23M 39.92M 40.9M 40.96M 40.84M 40.38M 40.45M 40.23M 40.04M 39M 39.1M 38.8M 38.68M 36.67M 29.93M 29.93M 27M
Shares Outstanding (Diluted)
42.61M 41.23M 39.92M 40.9M 41.59M 41.56M 40.51M 40.45M 40.23M 40.04M 39M 39.1M 38.8M 38.68M 36.67M 29.93M 29.93M 27M
EPS (Basic)
-0.61 -0.71 -0.48 0.11 0.51 0.26 0.18 -0.37 -0.48 -0.72 -0.95 -0.95 -0.99 -0.89 -0.79 -0.8 -0.7 -0.63
EPS (Diluted)
-0.62 -0.71 -0.48 0.11 0.51 0.26 0.18 -0.37 -0.48 -0.72 -0.95 -0.95 -0.99 -0.89 -0.79 -0.8 -0.7 -0.63
EBITDA
-4.09M -6.11M 546K 24.86M 25.49M 10.6M 3.25M -18.1M -23.87M -31.54M -37.61M -38.73M -37.95M -32.63M -26.23M -24.15M -19.9M -15.88M
EBIT
-4.24M -6.27M 353K 24.64M 27.73M 12.84M 5.51M -18.74M -26.93M -34.55M -40.6M -30.86M -30.08M -24.78M -18.4M -24.22M -16.81M -10.7M
Depreciation & Amortization
143K 167K 193K 215K 217K 215K 196K 3.09M 3.06M 3.02M 2.99M 53K 57K 70K 87K 77K 60K 35K